



Growth. Performance. Success. NCPA 2025 ANNUAL CONVENTION



1



Overcoming Common Audit Issues: A Team-Based Approach



NCPA 2025 Annual Convention and Expo

Speaker



Trenton Thiede PharmD, MBA

President

PAAS National® LLC



NCPA S

3

Disclosure Statement

There are no relevant financial relationships with ACPE defined commercial interests for anyone who was in control of the content of the activity.

This presentation contains product names and images for educational purposes only. It is not meant to be an endorsement or advertisement of any particular product product categories.



Pharmacist and Technician Learning Objectives


- 1. Discuss the most common PBM audit discrepancies
- 2. Examine audit discrepancies that result in the largest recoupment
- 3. Outline strategies for engaging pharmacy team members in preventing and responding to audits



NCPA PHARMACISTS ASSOCIATION

5

Why So Many Audits? Escalating Healthcare Costs Opioid Epidemic Contractual Requirements Fraud, Waste & Abuse Common Billing Errors Data Analytics/Outliers PBM Revenue Source = \$\$\$









Claims - GEICO sues Brooklyn pharmacy over \$3.5 million No-Fault fraud claims

GEICO sues Brooklyn pharmacy over \$3.5 million No-Fault fraud claims

GEICO alleges a Brooklyn pharmacy billed millions for unnecessary pain creams under New York's No-Fault system - and wants the court to stop future payments

12

NEWS



DOJ and HHS Form Working Group to Intensify Health Care Fraud Enforcement

Juliet Gallagher

07/02/2025











The US Department of Health and Human Services (HHS) and the US Department of Justice (DOJ) announced the formation of the DOJ-HHS False Claims Act (FCA) Working Group, a joint initiative designed to strengthen enforcement efforts against health care fraud. The False Claims Act has long been one of the most effective legal tools for addressing fraud, and this new working group formalizes a coordinated strategy to pursue high-priority violations.

Audit Trends 2020-2024*

Rx Invoice Onsite Desk **Validation** Virtual **Audits Requests** 7% 6% 2020 62% 23% 2% 2021 67% 20% 11% 0% 2% 2022 67% 21% 5% 5% 2% 2023 51% 37% 9% 2% 1% 49% 2024 38% 1% 9% 3%

19% increase in Onsite Audits YTD 2025

Many invoice audits are completed in tandem with desk/onsite audits

NCPA &

*Based on PAAS Audit Statistics

14



Insulin

Submit an accurate days' supply, when possible Mathematically calculable directions

- · Max daily dose
- Deliverable dose
 - o Generally, 1-unit increments
 - o Exceptions:
 - Humalog® Junior KwikPen (0.5 unit)
 - Toujeo® MAX SoloStar® (2 unit)
 - Tresiba® U-200 FlexTouch® (2 únit)
 - Humulin® R U-500 KwikPen (5 unit)



16

1. Days' Supply — Insulin/GLP-1

Insulin - Priming Units

- Not all third-party payors will use priming units in their days' supply calculations
- Document if priming units are used
- Not all insulin pens use a 2-unit prime

Insulin	Priming Units
Toujeo [®] SoloStar [®] (Insulin glargine)	3 units
Toujeo [®] Max SoloStar [®] (Insulin glargine)	4 units
Humulin [®] R U-500 KwikPen (insulin human injection)	5 units



https://www.dailymed.nlm.nih.gov/dailymed/

<u>Insulin Example</u>

- 1500 units per Carton
 - o 10 units/day = 150 days' supply
 - Each pen has 28-day Beyond Use Date (BUD) once in use
 - Actual days' supply would be 140 days
 - o If insurance rejects 140 days:
 - Call the helpdesk for an override
 - Document on the hard copy
 - Do NOT refill the prescription early
 - Recommend actual days' supply add to the end of the patient's instructions (i.e., SIG)

For June Jones (DOB 9/27/62) Date 01/05/2025

Address 123 Main St, Pharmtown, WI 55221

R

Lautus Solostar W-100

15 mL

Take 10 units SubQ at bedtime

Refills: 12

Dr. Dia Betes (NPI: 1234567)

NCPA STATIONAL COMMUNITY PHARMACISTS ASSOCIATION

https://www.dailymed.nlm.nih.gov/dailymed/

Address: 12 Sugarcreek Road, Pharmtown, WI 55221

Phone: <u>555-867-5309</u>

18

1. Days' Supply — Insulin/GLP-1

Insulin Example

- 1500 units per Carton; prescribed 2 cartons
 = 3000 units
 - o 30 units/day = 100 days' supply
- If insurance rejects 100 days:
 - o Call the help desk for an override
 - o Reduce the number of cartons to 1
 - i.e., bill 15 mL = 50 days' supply

For <u>James Smith (DOB 1/7/60)</u> Date <u>01/05/2025</u> Address <u>3 S. Fourth St, Pharmtown, WI 55221</u>

 P_{X}

Lantus Solostar U-100

30 mL

Inject 30 units SubQ nightly at bedtime

Refills: 11

Dr. Sue Gar (NPI: 1256891)

Address: 12 Sugarcreek Road, Pharmtown, WI 55221

hone: <u>555-867-5309</u>



https://www.dailymed.nlm.nih.gov/dailymed/

GLP-1s

- · Common pitfalls:
 - o Quantity
 - o Unit of measure
 - o Directions
 - o Days' Supply



20

1. Days' Supply — Insulin/GLP-1

Standard dosing

- Initial fil
 - o Billed with a 42 days' supply initially
 - o 2 mg per pen
 - o 0.25 mg per dose x 4 doses = 1 mg used
 - o 1 mg remaining ÷ 0.5 mg dose = 2 doses
 - o 6 doses x 1 dose/week = 6 weeks (42 DS)
- First refill
 - o Billed as a 28 days' supply
 - o Still using a 2 mg/3 mL pen
 - o 2 mg ÷ 0.5 mg dose = 4 doses
 - o 4 doses x 1 dose/week = 4 weeks (28 DS)

For <u>Ray Sun (DOB 11/5/70)</u> Date <u>01/05/2025</u> Address <u>356 N. Fourth St, Pharmtown, WI 55221</u>



Ozempic 2 mg|3 mL

3 mL

Inject 0.25 mg SubQ once weekly x 4 weeks, then increase to 0.5 mg weekly thereafter

Refills: 11

Dr. Sue Gar (NPI: 1256891)

Address: 12 Sugarcreek Road, Pharmtown, WI 55221


Phone: <u>555-867-5309</u>

https://www.dailymed.nlm.nih.gov/dailymed/



What about 0.25 mg SQ weekly, without the increase?

- Confirm dose with prescriber and document
- Use the 2 mg/3 mL pen which can deliver the 0.25 mg dose
- 2 mg ÷ 0.25 mg per dose = 8 doses
- 8 doses x 1 dose/week = 8 weeks or 56 days' supply
- Several large PBMs require 56 days' supply
 - Don't forget the pen needles!



NCPA STATIONAL COMMUNITY PHARMACISTS ASSOCIATION

https://www.dailymed.nlm.nih.gov/dailymed/

Phone: 555-867-5309

22

2. Days' Supply — Topicals

- Submit accurate DS if possible
- Mathematical instructions for use
 - o Grams per application (if one area only)
 - Max Daily Dose per MD or expected day supply
 - o List of affected areas + Finger Tip Unit (FTU) Method
- Collagenase use manufacturer dosing calculator



2. Days' Supply — Topicals

- FingerTip Unit (FTU) Method
- 1 FTU = 0.5 gram (adult)
- 1 FTU covers one hand (front/back)



# of FTUs		
1		
1		
4 (3+1)		
8 (7+1)		
4		
8 each		
2.5		



24

2. Days' Supply — Topicals


Vaginal Creams

- Submit accurate days' supply, when possible
- Directions must include grams/application and frequency
- Clarification required for the following:
 - o Pea sized
 - o 1 application three times weekly
 - o Insert three times weekly as directed

Product	Package Size	Applicator Measurements
Estrace® (estradiol) 0.01% vaginal cream	42.5 grams	1 to 4 grams (1 gram increments)
Premarin® (conjugated estrogens) vaginal cream	30 grams	0.5 to 2 grams (0.5 gram increments)

2. Days' Supply — Topicals

- As is, prescription did not have sufficient directions to mathematically calculate the days' supply
- Clarify + clinical note + update label
 - o Sample script: 30 grams
 - o ½ applicatorful of Premarin® = 1 gram
 - o 30 grams ÷ 2 grams/week = 15 weeks
 - o 15 weeks x 7 days/week = 105 days
 - o Plan limit? Watch refill interval!





26

3. Days' Supply - Inhalers

- Submit accurate DS if possible
- Do not refill early
- Strategies
 - o Call for DS override
 - o Add note to sig field (e.g., 60 Days' Supply)
 - o Train staff to watch for refill intervals
- Be mindful of undocumented Albuterol HFA substitutions



4. Days' Supply — Eye Drops

- Submit accurate DS if possible
- In general:
 - o 20 drops/mL for solution
 - o 15 drops/mL for suspension
- PBMs have their own "estimates"
 - o CVS/Caremark® 15 drops/mL
 - o Express Scripts® 16 drops/mLo OptumRx® 15-20 drops/mL
- Manufacturer guidance Miebo[®], Vevye[®] and Vyzulta[®]



Source: Respective PBM Provider Manuals (Caremark, Express Scripts, OptumRx)

28

5. DAW Codes

- NCPDP Field 408-D8
- Values 0-9
- Documentation must support use

Code	Description
0	No Product Selection Indicated
1	Substitution Not Allowed by Prescriber
2	Substitution Allowed – Patient Requested Product Dispensed
8	Substitution Allowed – Generic Drug Not Available in Marketplace
9	Substitution Allowed By Prescriber but Plan Requests Brand



5. DAW Codes

Use DAW 1 appropriately

- Not for single source brands, biologics without an interchangeable biosimilar or OTC items
- Generics without rationale
- · Careful with state/Medicaid requirements

Do not bill DAW 9 without explicit Plan direction or knowledge of PBM formulary preferences



30

6. Controlled Substances

- Federal Law
 - o 3 elements as per 21 CFR 1306.05(a)
 - Patient Address
 - MD Address
 - DEA Number
- State Law(s)
 - o Where applicable



7. Electronic Prescriptions

- Quantity
 - o "1" smallest package size
 - o Unit of Measure "unspecified"
- Erroneous DAW
- Default Days' Supply
- Invalid eRxs



32

8. Transfer Requirements

General Requirements

"Copy" or "Transfer"

Transferring pharmacy info – RPh, pharmacy, address, phone, DEA # Rx info

Rx history – Rx #, first/last fill, original/remaining refills

Your info – date of transfer, RPh



- Use a dedicated transfer Rx pad with all required elements
 - Data Entry original date vs. transfer date
 - · State specific laws/variations thereof



9. Migraine Medications

PRN Migraine Medications

- Specific directions for use and dosage form
- Estimated # of headaches per/week or month (particularly when > one package)
- FDA approved dosage range



34

35

9. Migraine Medications

Drug	FDA approved indications/usage	Recommend dose	Can patient repeat the dose?	Maximum daily dose	Billing Unit per package
Migranal Nasal Spray	Acute treatment	One spray in each nostril (must prime with 4 pumps prior to each use and discard 8 hours after it is primed)	Yes, 15 minutes later	No more than 4 sprays (2 mg) per 24 hours. No safety studies for doses > 3 mg/24 hours and 4 mg/7 days.	8 mL
Nurtec ODT tablets	Acute treatment	75 mg daily	No	No more than 18 doses in a 30-day	8 each
	Preventative treatment	75 mg every other day		period	o eacii
Ubrelvy tablets	Acute treatment	50 mg or 100 mg	Yes, at least 2 hours after initial dose	200 mg/24 hours and no more than 8 migraines in 30- day period	10 or 16 each

https://www.dailymed.nlm.nih.gov/dailymed

10. Proof of Dispensing and Copay Collection

Proof of Dispensing (in-person)

- Elements:
 - 1. Rx #
 - 2. Date of Service (or refill indicator)
 - 3. Date of Receipt
 - 4. Signature of Patient/Representative
- "Curbside" or "Drive Thru" notations by staff are not sufficient



36

10. Proof of Dispensing and Copay Collection

Proof of Dispensing (delivery)

- Elements:
 - 1. Patient name/address
 - 2. Rx #
 - 3. Date of Service (or refill indicator)
 - 4. Date of Delivery (handwritten or time-stamped)
 - 5. Signature of Patient/Representative
- Driver signature and geotag pictures are insufficient



10. Proof of Dispensing and Copay Collection

Copay Collection

- Contracts require collection WITH PROOF (limited exceptions)
- In-house charge accounts
- Manufacturer Coupons
 - o Medicaid/Medicare
 - o Caremark: non-FDA approved



38

QUESTION 1:

Which of the following is one of the most common audit discrepancies pharmacies face?

- a. Incorrect NPI
- b. Dispensing outside return to stock timeframes
- c. Incorrect days' supply
- d. Missing prescriptions



ANSWER 1: Which of the following the followi

Which of the following is one of the most common audit discrepancies pharmacies face?

- a. Incorrect NPI
- b. Dispensing outside return to stock timeframes
- c. Incorrect days' supply
- d. Missing prescriptions



41

Audit Issues Leading to Largest Recoupments

Drug Procurement

Prior Authorization Integrity

Dispense in the Original Container

Telemedicine


Template Forms


Refill too Soon







1. Drug Procurement











43

2. Prior Authorization Integrity

Most PBMs have language prohibiting the pharmacy from completing a prior authorization on behalf of a prescriber

- OptumRx will allow pharmacies to assist with prior authorizations if the pharmacy acquires an "appointment of representation"
- Express Scripts if the prescriber has authorized the Network Provider to assist in completing the PA on its behalf (must be in writing)



2. Prior Authorization Integrity



45

NCPA C

3. Dispense in Original Container

- Per the manufacturer's [FDA approved] labeling and package insert
- Approved language is not always clear
 - o Store in the original container
 - o Store and dispense in the original container
- Targeted Drugs include:
 - o Linzess (linaclotide)
 - o Pancreatic Enzymes
 - o Antiretroviral medications



4. Telemedicine

- Valid patient/prescriber relationship
- Prescriber licensed in state patient is located in
- Prescriber's scope of practice
- Proximity between patient, prescriber and pharmacy





47

5. Template Forms

- PBM concern about pharmacy soliciting prescriptions and influencing prescriber
 - o Small list of high AWP items, pain/scar compounds
 - Not individualized medicine identical quantities, sig and refills
- · Cascading or overly broad substitution language
- 2025 OptumRx Provider Manual, Version 2.1:
 - Dispensing or distributing Prescription Drugs/Drug Products which are not based on valid prescriptions for individually identified Members or are otherwise on pre-populated or templated prescriptions is prohibited.



6. Refill Too Soon for Unbreakable Packages

- PBMs often force the pharmacy to submit a value less than the actual day's supply
 - o For example, calculated DS is 80 days, but plan limit is 30 days
- Audit risk for refilling the prescription before the plan defined utilization threshold has been reached for the actual days' supply
- PBMs know the first days' supply adjudicated (80) is likely the accurate DS (even though the plan limit required is different), so when looking for claims to audit, PBMs will take the 80 days and multiply it by the utilization threshold to identify claims that are potentially 'refill too soon'

 The potential of the potenti
 - o This can lead to refills being fully recouped
- Targeted drugs include: Insulin/GLP-1, Topicals, Inhalers and Eye Drops



49

QUESTION 2:

A prescription for insulin calculates to an 80-day supply, but the plan only allows 30 days. The pharmacy refills it on day 31, and the PBM flags it as "refill too soon." Why?

- a. The pharmacy billed the wrong days' supply.
- b. PBMs audit based on the calculated days' supply (80 days), not the plan-limited amount.
- c. The refill was billed under the wrong NDC.
- d. The prescription directions were incorrect.



ANSWER 2:


A prescription for insulin calculates to an 80-day supply, but the plan only allows 30 days. The pharmacy refills it on day 31, and the PBM flags it as "refill too soon." Why?


- a. The pharmacy billed the wrong days' supply.
- b. PBMs audit based on the *calculated* days' supply (80 days), not the plan-limited amount.
- c. The refill was billed under the wrong NDC.
- d. The prescription directions were incorrect.





52




















OPEN RESPONSE: What's one workflow change your pharmacy team could implement tomorrow to reduce audit risk?

